Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Zelluna Immunotherapy logo — Developing allogeneic TCR-NK therapies for solid tumors

Zelluna Immunotherapy

Developing allogeneic TCR-NK therapies for solid tumors

Founded 2016 Norway Norway 25 employees Series Unknown Total: $7.50M Biotechnology, Health Care +1

General Information

Company Name Zelluna Immunotherapy
Founded Year 2016
Location Norway Norway
Founders / Decision Makers
Team member
Employees 25
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when Zelluna Immunotherapy moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Zelluna Immunotherapy

Zelluna is a Norway-based biotechnology company founded in 2016. The company is focused on pioneering allogeneic T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. Zelluna's slogan "Developing allogeneic TCR-NK therapies for solid tumors" encapsulates its mission. The company is dedicated to developing a portfolio of tumor-specific TCRs aimed at guiding NK cells to induce safe, efficient, and durable cancer responses. Zelluna recently received a Venture Round investment on 25 August 2022 from Takeda Pharma. For more information, please visit www.zelluna.com.

Taxonomy: Immunotherapy, Cancer treatment, Adoptive cell therapy, T cell receptor technologies, Solid tumors, Biopharmaceutical, Cellular therapy, Allogeneic TCR-NK therapies, GMP facilities, Oslo Cancer Cluster, Norwegian Radium Hospital, Research and development, Immunooncology, Norwegian biotechnology

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1
Investor
25 Aug 2022
Venture Round •••••• - 11 Jun 2020
Grant •••••• - 11 Jun 2020
Seed Round •••••• 1
Investor
01 Jan 2017

Zelluna Immunotherapy Alternatives & Competitors

Zelluna Immunotherapy vs
T Cell Nouveau
T Cell Nouveau Japan

Clinical stage biopharmaceutical company with novel TCR like CAR-T cell therapy for solid tumors at...

1 employees
Biopharma, Biotechnology
Compare Zelluna Immunotherapy vs T Cell Nouveau
Zelluna Immunotherapy vs
TC BioPharm
TC BioPharm United Kingdom

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

Post Ipo Equity
51 employees
Biotechnology, Health Care
Compare Zelluna Immunotherapy vs TC BioPharm
Zelluna Immunotherapy vs
Matterhorn Biosciences
Matterhorn Biosciences Switzerland

M-TCR cell therapies targeting a new hallmark of cancer

Series Unknown
7 employees
Biopharma, Biotechnology
Compare Zelluna Immunotherapy vs Matterhorn Biosciences

FAQ About Zelluna Immunotherapy

Developing allogeneic TCR-NK therapies for solid tumors
Zelluna Immunotherapy was founded in 2016.
Zelluna Immunotherapy is headquartered in Norway.
Zelluna Immunotherapy operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Zelluna Immunotherapy has approximately 25 employees.
Zelluna Immunotherapy has completed 4 funding rounds, raising a total of $7.50M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Zelluna Immunotherapy include T Cell Nouveau, TC BioPharm , Matterhorn Biosciences, Kite Pharma, CytoArm｜BsAb Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Zelluna Immunotherapy and T Cell Nouveau are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Zelluna Immunotherapy and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy